Company intelligence / Profile preview
Andros Pharmaceuticals Co., Ltd.
Zhubei, Taiwanandrospharma.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
APC101 completed Phase 2a clinical trials in Australia in 2020. APC201 is currently in Phase 1/2 clinical trials for arthritis. APC101 for head and neck postherpetic neuralgia received approval from Taiwan FDA to conduct Phase 2 clinical trials in 2024[10].
- Therapeutic areas
- OtherRheumatologyOncologyNeurology
- Modalities
- Topical drug delivery systemsNon-viral gene delivery systems
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →03
Partnerships
Hong Kong pharmaceutical company (unnamed) for LALP cream
Beyond the preview
Go deeper on Andros Pharmaceuticals Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Andros Pharmaceuticals Co., Ltd..